Best in Biotech 28 Dec 2020
A Year to Remember: The Biggest European Biotech News in 2020
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at…
Genfit
- Latest Posts
News and Trends 13 May 2020
Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon
Patients with the chronic liver disease NASH must now wait even longer for an approved treatment, after French biotech Genfit’s…
Interview 30 Jul 2019
The First Approved NASH Therapy?
Genfit is poised to become the first company to get a treatment for NASH to market -- something that could…
News and Trends 25 Jun 2019
Genfit’s NASH Drug to Be Developed in China in Deal Worth up to €200M
The US-Chinese company Terns Pharmaceuticals will develop and commercialize Genfit’s phase III drug elafibranor for the chronic liver disease NASH…
ADVERTISEMENT
News and Trends 27 Mar 2019
Genfit Gets Ready to Launch Drug for Untreated Liver Disease Raising €120M
After some big failures from its top competitors earlier this year, French company Genfit has done an IPO to prepare…
News and Trends 23 Jan 2018
NASH Leader goes Pediatric with Clinical Trial Launch in US
The FDA has cleared Genfit to kick off clinical trials to see if its NASH drug, elafibranor, can also help children.…
Best in Biotech 28 Dec 2017
Bored Between the Holidays? Watch these Biotech Videos!
Christmas might have passed, but we have more videos for you to watch on a dreary winter day! Here are…
News and Trends 17 Oct 2017
Genfit Gets €180M Cash Injection to Bring its Pipeline to Market
Elafibranor, Genfit's lead candidate, will continue its march towards the market with the added boost of massive financial support. Genfit is a…
Best in Biotech 26 Sep 2017
These Three Fields Are Proving Biotech is The Innovation Powerhouse in Healthcare
Biotech is the best source of innovation in R&D, making its companies the darlings of pharma. Which therapeutic fields belong…
Interview 11 Jul 2017
The Advantage for the First Mover in NASH is Limited, says Genfit
After we reviewed NASH earlier this year, Genfit's CSO, Dean Hum, came to speak at Refresh about his company's strategy…
News and Trends 24 Apr 2017
Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy
Genfit has announced that closing of enrollment will be delayed up to 6 months. Will this affect its chances to be…
News and Trends 18 Apr 2017
Two Big Pharma Players Team up to Take Over the NASH Space
Allergan has entered a clinical collaboration with Novartis to run a Phase IIb study combining its immunomodulator and Novartis' FXR agonist…
News and Trends 28 Mar 2017
Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?
Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor of “The First Gene Therapy”…
In Depth 7 Feb 2017
Not to be Underestimated: What’s the Hype around NASH?
Since 2014, investment in Non-Alcoholic SteatoHepatitis (NASH) has taken off with a fervor reminiscent of immuno-oncology. What’s it all about?…
News and Trends 26 Dec 2016
The Largest Deals, Fundraising and Exits of 2016 in European Biotech
Curious about which technologies have attracted the most cash in biotech finance this year? Here's a list of the most impressive cash…
News and Trends 7 Nov 2016
Green Light for Genfit to Tackle another Liver Disease
The FDA has cleared Genfit's IND application to treat a second liver disease with a big unmet clinical need. With…
ADVERTISEMENT
News and Trends 20 Sep 2016
Genfit’s Non-Invasive Diagnostic could unlock the NASH Market
Genfit reinforced its leading place in the race to find a cure for NASH when it announced this morning the launch…
News and Trends 31 Mar 2016
Beyond NASH: Genfit jumps into another Critical Liver Condition
Genfit is extending the applications of its star candidate, Elafibranor, to a second liver disease - Primary Biliary Cholangitis (PBC), a…
News and Trends 11 Mar 2016
Genfit Has Enroled its First Patient in a NASH Phase III Trial
Genfit (France) has enroled their first patient in the highly anticipated phase III trial (RESOLVE-IT) for NASH, a fatty-liver disease…
News and Trends 12 Jan 2016
10 Hot European Biotechs to watch in 2016
Looking forward to 2016, I wondered which Biotechs I would watch closely. Here's my list (which is not meant to…
